Premium Nahrungsergänzungsmittel | artgerecht

Organ Transplantation Markers – Definition and Relevance

Organ transplantation markers are medical parameters used before, during, and after an organ transplant to assess compatibility and monitor the success of the transplantation.

Regular tips about health Regular tips about health

Things worth knowing about "Organ Transplantation Markers"

Organ transplantation markers are medical parameters used before, during, and after an organ transplant to assess compatibility and monitor the success of the transplantation.

What Are Organ Transplantation Markers?

Organ transplantation markers are biological indicators – including genetic features, laboratory values, and immunological parameters – that play a central role in the preparation, execution, and follow-up care of an organ transplant. They help assess tissue compatibility between donor and recipient, detect rejection reactions at an early stage, and ensure long-term transplant success.

Types of Organ Transplantation Markers

HLA Antigens (Human Leukocyte Antigens)

The most important transplantation markers are HLA antigens (Human Leukocyte Antigens), also known as histocompatibility antigens. They are located on the surface of nearly all body cells and are used by the immune system to distinguish self from non-self tissue. The greater the match between donor and recipient HLA antigens, the lower the risk of a rejection reaction.

HLA-A, HLA-B, HLA-C: MHC class I antigens, relevant for cytotoxic T-cell responses
HLA-DR, HLA-DQ, HLA-DP: MHC class II antigens, particularly important for the activation of helper T-cells

Crossmatch Testing

The crossmatch test determines whether the recipient already has antibodies against cells from the prospective donor. A positive crossmatch indicates a high risk of rejection and may represent a contraindication to transplantation.

PRA Value (Panel Reactive Antibody)

The PRA value indicates the percentage of a representative donor population against which the recipient has already been sensitized. A high PRA value significantly complicates the search for a compatible donor organ.

Blood Group Compatibility

In addition to HLA markers, ABO blood group compatibility is a fundamental prerequisite for most organ transplantations. Incompatibility can lead to severe hyperacute rejection reactions.

Rejection Markers After Transplantation

After the transplant has been performed, various laboratory markers are used to monitor organ function and detect rejection reactions:

Creatinine and GFR: Key parameters for assessing kidney function after renal transplantation
Transaminases (ALT, AST), bilirubin: Liver values monitored after liver transplantation
Troponin and BNP: Heart-specific markers after cardiac transplantation
Donor-specific antibodies (DSA): Recipient antibodies directed specifically against donor organ characteristics, indicating humoral rejection
dd-cfDNA (donor-derived cell-free DNA): Free donor DNA in the recipient blood – a novel marker that can indicate organ injury or rejection at an early stage

The Role of Immunosuppression

Based on transplantation markers, immunosuppressive therapy is tailored individually to each patient. Medications such as ciclosporin, tacrolimus, mycophenolate mofetil, and corticosteroids suppress the recipient immune system to protect the transplanted organ. Regular drug level monitoring of these medications is also part of the overall surveillance and can be considered functional transplantation markers.

Clinical Relevance

Consistent monitoring of organ transplantation markers is essential for long-term transplant success. It enables early detection of:

Acute and chronic rejection reactions
Infections arising from immunosuppressive therapy
Toxicity caused by immunosuppressants
Long-term damage to the transplanted organ

References

Halloran PF. - Immunosuppressive drugs for kidney transplantation. New England Journal of Medicine, 2004; 351(26): 2715-2729.
Tait BD et al. - Consensus Guidelines on the Testing and Clinical Management Issues Associated with HLA and Non-HLA Antibodies in Transplantation. Transplantation, 2013; 95(1): 19-47.
Stites DP, Terr AI, Parslow TG. - Medical Immunology. 10th ed. McGraw-Hill, 2001.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.